Benzinga | Jan 5, 2021 07:32AM EST

Accuray Receives 510(k) FDA Clearance For ClearRT Helical kVCT Imaging For Radixact Treatment Delivery System

SUNNYVALE, Calif., Jan. 5, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ClearRT(tm) Helical kVCT Imaging* for the Radixact(r) System, the next generation TomoTherapy(r) platform. ClearRT is a cutting-edge imaging solution integrated with a powerful, precise, and adaptive delivery platform, designed to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively, to improve patient care. Accuray is planning commercial release of the ClearRT Helical kVCT Imaging for the Radixact System in the Spring of 2021.